ClinicalTrials.gg
CompletedNCT06688045Updated Nov 14, 2024

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

A Phase 1 interventional study of Nemtabrutinib and Itraconazole in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Oct 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The goal of this study is to learn what happens to levels of nemtabrutinib in a person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called itraconazole.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health based on medical history, physical examination, vital sign (VS) measurements, (ECGs) and laboratory safety tests performed before allocation.
  • Has a (BMI) of18 to 32 kg/m\^2 (inclusive)

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Has a history of cancer ().
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Period 1: Nemtabrutinib

    Participants receive a single oral dose of nemtabrutinib followed by a protocol specified wash-out period.

    Drug: Nemtabrutinib

  • Experimental
    Period 2: Nemtabrutinib + Itraconazole

    Participants receive oral doses of itraconazole once daily on Days 1 to 13 with a single oral dose of nemtabrutinib given with itraconazole on Day 4.

    Drug: Nemtabrutinib · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Nemtabrutinib

    Blood samples will be collected to determine the AUC0-inf of nemtabrutinib in plasma.

    Time frame: At designated time points (up to approximately 10 days postdose)

  2. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of Nemtabrutinib

    Blood samples will be collected to determine the AUC0-last of nemtabrutinib in plasma.

    Time frame: At designated time points (up to approximately 10 days postdose)

  3. Maximum Plasma Concentration (Cmax) of Nemtabrutinib

    Blood samples will be collected to determine the Cmax of nemtabrutinib in plasma.

    Time frame: At designated time points (up to approximately 10 days postdose)

  4. Time of Maximum Plasma Concentration (Tmax) of Nemtabrutinib

    Blood samples will be collected to determine the Tmax of nemtabrutinib in plasma.

    Time frame: At designated time points (up to approximately 10 days postdose)

  5. Apparent Terminal Half-life (t1/2) of Nemtabrutinib

    Blood samples will be collected to determine the t1/2 of nemtabrutinib in plasma.

    Time frame: At designated time points (up to approximately 10 days postdose)

  6. Apparent Clearance (CL/F) of Nemtabrutinib

    Blood samples will be collected to determine the CL/F of nemtabrutinib in plasma.

    Time frame: At designated time points (up to approximately 10 days postdose)

  7. Apparent Volume of Distribution (Vz/F) of Nemtabrutinib

    Blood samples will be collected to determine the Vz/F of nemtabrutinib in plasma.

    Time frame: At designated time points (up to approximately 10 days postdose)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 6 weeks

  2. Number of Participants Who Discontinue from Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 6 weeks

07

Study locations

1 site
  • Labcorp Clinical Research Unit Inc. (Site 0001)
    Honolulu, Hawaii 96813, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jan 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Oct 30, 2023
Primary completionActual
Jan 6, 2024
CompletionActual
Jan 6, 2024
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06688045
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Oct 30, 2023
Primary completion
Jan 6, 2024
Completion
Jan 6, 2024
Last update
Nov 14, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARQ531

Start the discussion